Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||NKTR-214 + NKTR-262|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NKTR-214||Bempegaldesleukin|Bempeg||Bempegaldesleukin (NKTR-214) comprises IL2 bound to polyethylene glycol, which stimulates anti-tumor immune response, potentially resulting in decreased tumor growth (PMID: 26832745, PMID: 32723187).|
|NKTR-262||NKTR262|NKTR 262||NKTR-262 is small molecule that targets the Toll-like receptor 7/8 pathway, triggering an innate immune response and the release of tumor antigens, which potentially leads to tumor regression when combined with a checkpoint inhibitor (Journal for ImmunoTherapy of Cancer 2017, 5 (Suppl 2):87 #P275).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03435640||Phase Ib/II||NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262||A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies||Recruiting|